FDA confirms increased risk of heart swelling with vaccine

 FDA confirms increased risk of heart swelling with vaccine


the FDA conducted a rigorous evaluation of the post-authorization safety surveillance data pertaining to myocarditis and pericarditis following administration of the Pfizer-BioNTech COVID-19 Vaccine and has determined that the data demonstrate increased risks, particularly within the seven days following the second dose. The observed risk is higher among males under 40 years of age compared to females and older males. 


fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine


some individuals required intensive care support. Information is not yet available about potential long-term health outcomes. The Comirnaty Prescribing Information includes a warning about these risks.


fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine


http://web.archive.org/web/20210823134524/fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine


Comments

Popular posts from this blog

Blood Clotting and COVID 19 Vaccine

COVID vaccination and age-stratified all-cause mortality risk

Archbishop letter about Covid 19 to President Donald Trump